Effectiveness of Sugammadex on muscle relaxant reversal in preterm neonates

Figures & data

Figure 1. The CONSORT flow chart of the studied patients.

Table 1. Demographic data of the studied patients.

	Mean± SD		P value
	Group N (n = 30)	Group S (n = 30)
Age/days Mean ±SD Range	13.8 ± 7.15 2–27	14.77 ± 7.69 2–27	0.616
Weight/ Kg Mean ±SD Range	2.38 ± 0.27 1.9–2.9	2.35 ± 0.29 1.8–2.8	0.649
Gestation age/weeks Mean ±SD Range	34.1 ± 0.84 33–36	33.86 ± 0.97 32–35	0.363
Sex (M: F)	23:7	20:10	0.391

Table 2. Total dose of muscle relaxant, reversal, and recovery times among the studied groups.

	Studied groups
	Group N (n = 30)	Group S (n = 30)	P value
Total dose of muscle relaxant (mg) Mean ±SD Range	0.47 ± 0.047 0.4–0.5	0.46 ± 0.049 0.4–0.5	0.388
Reversal time (in sec) Mean ±SD Range	8.9 ± 1.6 5.5–11	1.15 ± 0.42 0.5–2	<0.001*
Recovery time (in sec) Mean ±SD Range	27.16 ± 9.26 15–45	17 ± 6.64 10–30	<0.001*

Data were expressed by using mean ±SD.

P value for comparing between the two studied groups using t-test

*: statistically significant at p ≤ 0.05.

Figure 2. a, b. Reversal and recovery times distribution among the studied groups.

Figure 3. Mean heart rate (a) and mean arterial pressure (b) before reversal and 3–18 minutes after reversal.